Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1087MR)

This product GTTS-WQ1087MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1087MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5294MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ7918MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ8205MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ12254MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ13355MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ12379MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ9433MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ10046MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA L19-IL-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW